Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.69 |
| ▸ | LCK | P06239 | 4/20 | 0.69 |
| ▸ | FYN | P06241 | 4/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.69 |
| ▸ | KIT | P10721 | 4/20 | 0.69 |
| ▸ | FLT1 | P17948 | 4/20 | 0.69 |
| ▸ | FLT4 | P35916 | 4/20 | 0.69 |
| ▸ | KDR | P35968 | 4/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | RAF1 | P04049 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700542 | 1.00 | BRAF (0.69) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL13559541 | 1.00 | BRAF (0.69) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL6701432 | 0.92 | BRAF (0.69) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL6701429 | 0.92 | BRAF (0.69) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL13559539 | 0.92 | BRAF (0.69) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL6701141 | 0.90 | BRAF (0.65) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL6701146 | 0.90 | BRAF (0.65) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL13559518 | 0.90 | BRAF (0.65) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL6700934 | 0.88 | BRAF (0.58) | BRAFLCKFYNPDGFRBKIT | |
| SCHEMBL13559546 | 0.88 | BRAF (0.58) | BRAFLCKFYNPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | BRAF 1/4885LCK 250/4885FYN 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.